Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Expert Perspective on CDK4 Inhibitors

2017 ESMO Congress
Tweet this page

Sibylle Loibl, MD, PhD, of the German Breast Group, summarizes a session she chaired in which the rationale to target CDK4, data on efficacy of the inhibitors, and triple combination therapy with PI3K were discussed.

Advertisement

Advertisement



Advertisement